Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with one of the following cancers, confirmed by a pathology report at the time of screening: Merkel cell carcinoma, mucosal melanoma, basal cell carcinoma, or certain rare skin cancers (squamous cell carcinoma)
- People aged 18 or older
- People whose cancer is at a stage where surgery is either already planned, or may become possible if the cancer responds to treatment given beforehand (specific staging requirements differ depending on cancer type — confirm with trial site)
- People for whom a surgeon has described a planned surgical removal of the cancer
- People whose cancer has been tested for its genetic makeup (or where this has been attempted)
- People for whom a standard treatment plan involving immunotherapy or other medicines before surgery is planned, depending on cancer type (confirm specific treatment plans with trial site)
- People who have provided signed consent to participate in the trial
Who may not be able to join:
- People whose cancer has spread (metastasised) in a way that cannot be fully removed by surgery
- People who have received immunotherapy, chemotherapy, or radiation therapy for their specific cancer within the past year
- People with a significant medical condition that, in their treating doctor's judgement, would make immunotherapy unsafe
- People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the study period and up to 120 days after the last dose of treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Claire F Verschraegen, MD, Ohio State University Comprehensive Cancer Center
Phone: 800-293-5066
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time spent obtaining approval and drugs; Means of coverage; Out of pocket expenses for patients; Extent of surgical resection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.